跳至主要内容
临床试验/NCT00943098
NCT00943098已完成3 期

Efficacy and Safety of a Single s.c. Diclofenac HPBCD 75mg/1ml Injection as Compared to a Single i.m. Voltarol® 75mg/3ml, in the Treatment of Acute Moderate-to-severe Post-surgical Pain Following Dental Surgery (Impacted 3rd Molar Removal).

IBSA Institut Biochimique SA3 个研究点 分布在 1 个国家目标入组 142 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
142
试验地点
3
主要终点
Pain Intensity Difference (PID)

研究概览

简要总结

The present study is aimed at demonstrating the therapeutic equivalence of diclofenac HPBCD 75mg/1ml s.c. with the marketed reference product, Voltarol® 75mg/3ml i.m. in the treatment of acute moderate-to-severe pain after dental impaction surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.
  • Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.
  • Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.

排除标准

  • Surgery performed under general anaesthesia, or sedation.
  • Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.
  • Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.
  • Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.
  • Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.
  • Hepatic or renal impairment.
  • Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.
  • Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.
  • Patients under chronic treatment with topical or systemic analgesics/NSAIDs.
  • Patients under treatment with any medication that may affect the treatment efficacy evaluation.
  • Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.

研究组 & 干预措施

Voltarol 75mg/3ml i.m.

Active Comparator

干预措施: Voltarol 75mg/3ml i.m. (Drug)

Diclofenac HPBCD s.c. 75mg/ml

Experimental

干预措施: Diclofenac HPBCD s.c. 75mg/ml (Drug)

结局指标

主要结局

Pain Intensity Difference (PID)

时间窗: 1.5 hours

Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assessed by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).

次要结局

  • PIDs(at 8 hours post-dose.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验